Macrogenics Profit Margin

Macrogenics (MGNX) currently reports a profit margin of -44.79% as of March 2026. That compares with -36.62% in the prior-year period — down 22.3% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Macrogenics's profit margin history and peer comparisons.

Macrogenics's profit margin decreased from -36.62% to -44.79% — a 22.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Macrogenics's profit margin of -44.79% is lower than the Healthcare sector average of 15.58%. That is roughly 387.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Macrogenics's current -44.79% should be judged against Healthcare norms (sector average: 15.58%) and against MGNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -44.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Macrogenics, and consider following MGNX for alerts when major investors trade the stock.